a Carboplatin+oxaliplatin: 2 patients;
Cisplatin+nedaplatin/lobaplatin/carboplatin: 3 patients;
Nedaplatin+lobaplatin: 1 patient.
Table
S2. The association of baseline factors with post-recurrence survival in
patients treated with PARPi monotherapy and platinum-based
chemotherapy.